WAVEMAN · COMPANY

INDP · Indaptus Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

INDP

Name: Indaptus Therapeutics, Inc. (INDP) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Indaptus Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001857044

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

8 funds added or opened last quarter

below 89% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

0.1% of shares outstanding short · 1.1 days to cover · settled 2026-07-31

below 89% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Yao Yun disclosed a 5%+ stake (37.8%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -81.0%

-81.0%12M

13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 8 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Indaptus Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Anderson Glen R.

—

BUY

2023-08-14

23,934.0

$56.0K

Anderson Glen R.

—

BUY

2023-08-11

35,064.0

$74.3K

Anderson Glen R.

—

BUY

2023-08-10

44,354.0

$86.0K

Litchev Boyan Vesselinov

Chief Medical Officer

BUY

2022-12-01

500.0

$935

Litchev Boyan Vesselinov

Chief Medical Officer

BUY

2022-11-22

500.0

$915

18 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 13 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

GEODE CAPITAL MANAGEMENT, LLC

56,470.0 sh

$169.4K

JANE STREET GROUP, LLC

53,811.0 sh

$161.4K

VANGUARD CAPITAL MANAGEMENT LLC

33,652.0 sh

$101.0K

VANGUARD FIDUCIARY TRUST CO

13,967.0 sh

$41.9K

MILLENNIUM MANAGEMENT LLC

11,586.0 sh

$34.8K

5%+ owners

13D = intent to influence · 13G = passive

Yao Yun

ACTIVIST 13D · 2026-03-30

37.8%

SINO LION VENTURES Ltd

ACTIVIST 13D · 2026-03-30

35.0%

Xu Chenhao

ACTIVIST 13D · 2026-03-30

35.0%

Dai Junyi

ACTIVIST 13D · 2026-03-30

10.1%

Yang Ting

ACTIVIST 13D · 2026-03-30

10.1%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$16.9K POSITION · AS OF 2026-02-28

0.0%

Fidelity Series Total Market Index Fund

$1.1K POSITION · AS OF 2026-02-28

0.0%

Fidelity Total Market Index Fund

$966 POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Multi-phase

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Jeffrey A. Meckler

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$2.2M

$2.1M

$1.8M

-88%

—

2024

$1.2M

$1.0M

$949.6K

-52%

—

2023

$1.0M

$1.1M

$744.0K

+21%

—

2022

$1.7M

-$38.4K

$1.1M

-75%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
OPERATING INCOME	$-19.8M	$-15.4M	$-16.4M	$-14.9M
NET INCOME	$-20.8M	$-15.0M	$-15.4M	$-14.3M
EPS (DILUTED)	-21.58	-44.96	-1.83	-1.73
OPERATING CASH FLOW	$-14.8M	$-12.3M	$-13.4M	$-13.1M
CASH	$8.5M	$5.8M	$13.4M	$9.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE